Rigel Pharmaceuticals and Proteros extend research collaboration
23 April 2009
German company Proteros biostructures GmbH has announced an update on
the research collaboration with Rigel Pharmaceuticals Inc. From the
start of the collaboration allowing Rigel access to Gallery Structures,
Proteros has consistently delivered high quality protein-ligand
structural information which enables determination of the binding
characteristics of compounds supplied by Rigel to facilitate subsequent
compound optimisation.
Proteros has collaborated with Rigel since 2007 to solve the
structures of multiple proteins, selected by Rigel from Proteros’
Gallery Structures collection, in combination with compounds and
fragments supplied by Rigel to determine the binding mode of these
compounds to the selected protein and enable the rapid and informed
optimisation of the compounds and build up of the fragments.
By accessing Proteros’ Gallery Structures, a collection of seventy
five industry relevant proteins pre-established at Proteros, rapid
delivery of high quality protein-ligand structural information is
assured.
Timely availability of such protein-ligand structure information has
been an important element enabling Rigel’s scientists to accelerate
entire drug discovery programmes. The financial terms of the
collaboration which include research and success fees are not disclosed.
Bookmark this paget>